BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar Sells 27,389 Shares

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Neil Kumar sold 27,389 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $22.41, for a total transaction of $613,787.49. Following the completion of the sale, the chief executive officer now directly owns 4,897,443 shares of the company’s stock, valued at $109,751,697.63. This trade represents a 0.56 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

BridgeBio Pharma Stock Up 2.2 %

Shares of NASDAQ:BBIO opened at $23.04 on Thursday. The stock’s 50-day moving average is $25.09 and its 200-day moving average is $26.31. BridgeBio Pharma, Inc. has a 52-week low of $21.62 and a 52-week high of $44.32.

Institutional Trading of BridgeBio Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bfsg LLC boosted its position in shares of BridgeBio Pharma by 175.6% in the second quarter. Bfsg LLC now owns 1,240 shares of the company’s stock valued at $31,000 after acquiring an additional 790 shares during the period. Headlands Technologies LLC acquired a new position in BridgeBio Pharma during the 2nd quarter valued at $48,000. Values First Advisors Inc. acquired a new position in BridgeBio Pharma during the 3rd quarter valued at $57,000. CWM LLC boosted its holdings in BridgeBio Pharma by 132.9% in the 3rd quarter. CWM LLC now owns 3,442 shares of the company’s stock valued at $88,000 after purchasing an additional 1,964 shares during the period. Finally, EntryPoint Capital LLC acquired a new stake in BridgeBio Pharma in the 1st quarter worth $117,000. Institutional investors and hedge funds own 99.85% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on BBIO shares. Oppenheimer began coverage on shares of BridgeBio Pharma in a research report on Thursday, October 3rd. They issued a “market perform” rating for the company. Leerink Partners reduced their price objective on BridgeBio Pharma from $47.00 to $46.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $70.00 price target on shares of BridgeBio Pharma in a research note on Monday, September 16th. HC Wainwright reissued a “buy” rating and issued a $43.00 price target on shares of BridgeBio Pharma in a research note on Friday, October 25th. Finally, Bank of America reaffirmed a “buy” rating and set a $42.00 price objective on shares of BridgeBio Pharma in a research report on Wednesday, September 11th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $47.57.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.